The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Japan’s 1st Insulin Biosimilar Launched: Eli Lilly Japan, NBI
August 4, 2015
- Fuji Pharma to Obtain Marketing Rights for 3 Imaging Agents from Guerbet Japan
August 4, 2015
- Kyowa Kirin to Draw Up 5-Year Midterm Plan Focusing on Development of Global Products: President Hanai
August 4, 2015
- MTPC Files Edaravone for Amyotrophic Lateral Sclerosis in South Korea
August 4, 2015
- Kyowa Kirin’s Pharma Business Sales Up 13% Driven by New Products, Overseas Business in 1st Half of FY2015
August 3, 2015
- JCR Files for Growject Liquid Formulation
August 3, 2015
- Ono Files Opdivo for Use in Chemotherapy-Naïve Patients
August 3, 2015
- Post-Marketing Study Shows No Causal Relationship of Actos with Bladder Cancer: Takeda
August 3, 2015
- Novartis Files NDA for Acromegaly Treatment Pasireotide in Japan
August 3, 2015
- Bayer Yakuhin Files Nexavar to Expand Indication for Thyroid Cancer
August 3, 2015
- Otsuka Holdings Increases Forecasts for 1st Half of FY2015
August 3, 2015
- Wholesalers Must Ponder Use of Reps for New Business: Mediceo CEO
July 31, 2015
- Nichi-Iko to Tie Up with Thai Drug Maker to Strengthen Lineup, Accelerate Brand Penetration
July 31, 2015
- Nippon Kayaku Initiates PIII Study of Herceptin Biosimilar in Japan
July 31, 2015
- Sumitomo Dainippon’s Leigh Syndrome Drug Showed No Statistical Difference in PIIb Study in US
July 31, 2015
- Cresemba Fails to Meet Primary Endpoint in PIII Study for Candidemia: Astellas
July 31, 2015
- Eisai Files Halaven for Soft Tissue Sarcoma Simultaneously in Japan, US, Europe
July 31, 2015
- Kyowa Kirin Files NDA for Brodalumab for Psoriasis in Japan
July 31, 2015
- Kyowa Kirin, BMS to Collaborate in Study of Combination Poteligeo, Opdivo in US
July 31, 2015
- AbbVie Pres. Says Japan Attracting Foreign Investments, Confident in Hep C Drug
July 31, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…